Our findings demonstrated that NEAT1 siRNA3 enhanced the sensitivity of NSCLC cells to anlotinib by inhibiting the Wnt/β-catenin signaling pathway. This evidence concerns the gene NEAT1 and non-small cell lung carcinoma.